Please login to the form below

Not currently logged in
Email:
Password:

Omthera Pharmaceuticals

This page shows the latest Omthera Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA approves AZ’s fish oil drug

FDA approves AZ’s fish oil drug

It was originally developed by Omthera Pharmaceuticals – a biotech AZ purchased for $443m in 2013.

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... AZ acquired Epanova along with developer Omthera Pharmaceuticals in July 2013 in a $443m

  • Soriot says pipeline will speed recovery at AZ Soriot says pipeline will speed recovery at AZ

    Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.

  • AZ said to be eyeing Forest takeover bid AZ said to be eyeing Forest takeover bid

    $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    Hypertriglyceridaemia treatment acquired as part of Omthera takeover. AstraZeneca (AZ) is starting to see the fruits of its series of pipeline-boosting acquisitions in the past year with US regulators accepting ... Review is expected to be completed by

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    Therapeutics in a $1.15bn deal along with US biotechs AlphaCore Pharma and Omthera Pharmaceuticals earlier this year.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    closely followed by Omthera Pharmaceuticals' Epinova, not to mention the growing concerns regarding the health benefits of premium priced prescription omega-3 fatty acids. Perhaps this is reflected in an offer ... Discovery research alliance.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics